Service Standard for the Right to Sell Drugs under the Food and Drug Regulations – Health Canada
Health Canada posts service standards and performance information for services with over 100 regulatory authorizations, such as permits or licences, issued each year (high-volume regulatory transactions).
Before a drug is authorized for sale in Canada, it must be issued a Drug Identification Number (DIN) in accordance with section C.01.014.2 or C.08.002 of the Food and Drug Regulations. Also in accordance with section C.01.014.5 of the Food and Drug Regulations, a manufacturer of a drug must annually, before October 1, notify Health Canada that the drug is still on the market and that all the information previously provided pertaining to the drug is correct.
The Fees for the Right to Sell Drugs guidance document provides manufacturers and regulatory correspondents guidance on the step by step process for annual notification in accordance with section C.01.014.5 of the Food and Drug Regulations.
The Health Products and Food Branch (HPFB) commits to service delivery standard of 120 calendar days, from the receipt of annual notification, to update the Drug Product Database.
The target for achieving this standard is set at 100% of updates made within the applicable review timelines.
Performance result for fiscal year 2020 to 2021:
Annual service performance is measured over the course of the fiscal year (April 1 - March 31). Performance results for a given fiscal year are published in the Report on Fees, which is normally tabled in Parliament and published in the third quarter (October-December) of the following fiscal year.
In 2020-2021, HPFB's actual result for these updates was 100% made within 120 calendar days.
To make any general inquiries or comments, please contact:
Office of Submissions and Intellectual Property
Resource Management and Operations Directorate
On Cost Recovery:
Report a problem or mistake on this page
- Date modified: